NCT06103695Completed
Vtama in Psoriasis Patients Being Treated With Biologics.
Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.
Psoriasis Treatment Center of Central New JerseyPhase 4ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Psoriasis
- Drug/Device/Intervention
- Tapinarof
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Psoriasis Treatment Center of Central New Jersey
- Location
- East Windsor, United States of America
Timeline & enrollment
- Phase
- Phase 4
- Start date
- Feb 27, 2023
- End date
- Oct 18, 2023
- Enrollment
- 30 participants
Primary outcome
Body surface area ≤1%
Summary
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients
 with ≥3% BSA who have received biologic therapy for at least 24 weeks.
ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06103695
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06103695 through Pure Global AI's free database. This Phase 4 trial is sponsored by Psoriasis Treatment Center of Central New Jersey and is currently Completed. The study focuses on Psoriasis. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.